Clinical Practice

Use the tool below to view all available Global Neurology Academy Series

Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
CME/CE Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Learn more
CME/CE In-Person Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
Learn more
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
NeuroFrontiers
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
- Aaron Miller, MD
Nutrition and the Gut-Brain Connection in Schizophrenia
Nutrition and the Gut-Brain Connection in Schizophrenia
On the Frontlines of Schizophrenia
Nutrition and the Gut-Brain Connection in Schizophrenia
- Shelina Ramnarine, PhD
- Deanna L. Kelly, PharmD, BCPP
The Social Brain in Schizophrenia
The Social Brain in Schizophrenia
On the Frontlines of Schizophrenia
The Social Brain in Schizophrenia
- Shelina Ramnarine, PhD
- Michael Green, PhD
Emerging Serum microRNAs as Early Signals in MS
Emerging Serum microRNAs as Early Signals in MS
NeuroFrontiers
Emerging Serum microRNAs as Early Signals in MS
Family Planning in Patients with Multiple Sclerosis
Family Planning in Patients with Multiple Sclerosis
NeuroFrontiers
Family Planning in Patients with Multiple Sclerosis
Strengthening Global Infrastructure for FSHD Trials
Strengthening Global Infrastructure for FSHD Trials
AudioAbstracts
Strengthening Global Infrastructure for FSHD Trials
- Marlene Mimi Maeusli, PhD.
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Rethinking Progression in Multiple Sclerosis
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Lock, MD
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
- Alexandria May, PharmD, BCPS
- Apurva Bhatt, MD

Clinical Practice

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

Clinical Practice

Popular

Title

Share on ReachMD